UBS Assumes Myriad Genetics (MYGN) at Neutral
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.20 +0.63%
Rating Summary:
6 Buy, 19 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 60
Rating Summary:
6 Buy, 19 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 60
Join SI Premium – FREE
UBS analyst Douglas Schenkel assumes coverage on Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and a price target of $3.60.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $3.18 yesterday.
You May Also Be Interested In
- BWS Financial Starts Twist Bioscience (TWST) at Sell, 'Insider selling activity picked up steam'
- H.C. Wainwright Starts TriSalus Life Sciences, Inc. (TLSI) at Buy
- TD Cowen Starts Faeth Therapeutics (FTH) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
